A Phase 2 interventional study of SRX246 and Placebo in Irritable Mood and Huntington's Disease, sponsored by Azevan Pharmaceuticals. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by Azevan Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.
Among the 138 studies in Huntington Disease with a site in United States, this one is the 29th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2016, is one of 28 in phase 2, and was the 67th registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:
Prilenia · Sites in United States, Belgium, Canada and 9 more countries
Ages 23–65
Leslie Thompson · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 24 more countries
Ages 21–70
Skyhawk Therapeutics, Inc. · Sites in United States, Argentina, Brazil and 7 more countries
Ages 25+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 39 · Phase 3 17 · Phase 4 3
First in 1999; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.
Median enrollment 44 across the 90 interventional studies, 131 across the 48 observational. Of the 99 that completed or were terminated, 36 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 138 have an industry lead sponsor. The 10 most frequent:
Azevan Pharmaceuticals is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Azevan Pharmaceuticals has 1 study filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Huntington Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04713982Phase 3Vanderbilt University Medical CenterImpact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | 2027-06-30 |
| NCT06843252The University of Texas Health Science Center at San AntonioHome-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease | 2026-12 |
| NCT06475898Huntington Study GroupLongitudinal Endpoint Assessment of Disease Burden in HD | 2026-12 |
| NCT05326451The University of Texas Health Science Center, HoustonHome-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease | 2026-12-31 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 138 studies in Huntington Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease. Two-thirds of all participants will receive SRX246, while the other third will receive a placebo.
SRX246 is a first-in-class vasopressin 1a (V1a) receptor antagonist that crosses the blood-brain barrier following oral administration. The molecule exhibits high affinity and high selectivity for its target receptor. Preclinical pharmacology studies have demonstrated significant CNS effects in models of irritability, including impulsive aggression, depression, and anxiety. In an experimental medicine fMRI study in healthy volunteers, SRX246 treatment significantly attenuated the effect of intranasal AVP in brain circuits known to modulate emotional responses to stimuli that elicit aggression/fear. Together, these findings suggest that SRX246 has potential as a novel therapeutic agent for major neuropsychiatric symptoms seen in HD patients.
This is a 3-arm, multicenter, randomized, placebo-controlled, double-blind, 12 week, dose escalation study of SRX246 in irritable Subjects with early symptomatic HD.
Following an initial screening visit, Subjects fulfilling the study inclusion and exclusion criteria will enter a pre-treatment screening phase to permit evaluations to confirm eligibility for inclusion into the study. This screening phase will be no longer than 30 days. At the completion of the screening period, eligible Subjects will be randomized at baseline visit to receive either placebo or final doses of SRX246 of 120 mg twice daily or 160 mg twice daily during the double-blind treatment phase. At baseline, Subjects in the active groups will receive 80 mg twice daily for 2 weeks, then escalate to 120 mg twice daily for 4 weeks. Then one group of Subjects will continue to take 120 mg of SRX246 twice daily for an additional 6 weeks, and the second group of Subjects will increase their dose to 160 mg of SRX246 twice daily for 6 weeks. Total dosing duration is 12 weeks.
Subjects in the placebo group will receive a similar number of capsules that are identical in appearance to the capsules that contain SRX246 during the trial, in order to preserve the blind.
In all groups, dose escalation will occur (stepwise) if patients have not experienced dose-limiting adverse effects. Patients who cannot tolerate their final dose of drug (or placebo) can have this dose reduced without compromising the blinding.
Subjects will have periodic visits either "in-person" or by "telephone", to assess tolerability, safety, and several measures of irritability and other problem behaviors, and clinical assessments for activity signals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SRX246 capsules, administered orally, in divided doses twice daily
Drug: SRX246
SRX246 capsules, administered orally, in divided doses twice daily
Drug: SRX246
Placebo capsules, administered orally, in divided doses twice daily
Drug: Placebo
Tolerability of SRX246
The primary endpoint, tolerability of SRX246, was assessed by the number of completers in each group.
Time frame: 12 weeks
Safety of SRX246
The Safety of SRX246 was assessed by the number of participants who experience an adverse event.
Time frame: 12 weeks
| Milestone | SRX246 120mg BID | SRX246 160mg BID | Placebo |
|---|---|---|---|
| Started | 36 | 34 | 36 |
| Completed | 25 | 27 | 30 |
| Not completed | 11 | 7 | 6 |
The primary endpoint, tolerability of SRX246, was assessed by the number of completers in each group.
| Participants | SRX246 120mg BID | SRX246 160mg BID | Placebo |
|---|---|---|---|
| Tolerability of SRX246 | 25 | 27 | 30 |
The Safety of SRX246 was assessed by the number of participants who experience an adverse event.
| Participants | SRX246 120mg BID | SRX246 160mg BID | Placebo |
|---|---|---|---|
| Safety of SRX246 | 29 | 30 | 26 |
Collected over From first dose of study drug to last date of patient follow-up at end of study (an average of 12-weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SRX246 120mg BID | 0/36 (0%) | 5/36 (13.9%) | 29/36 (80.6%) |
| SRX246 160mg BID | 0/34 (0%) | 0/34 (0%) | 30/34 (88.2%) |
| Placebo | 0/36 (0%) | 0/36 (0%) | 26/36 (72.2%) |
| Event | SRX246 120mg BID | SRX246 160mg BID | Placebo |
|---|---|---|---|
| Aggression and IrritabilityPsychiatric disorders | 2/36 | 0/34 | 0/36 |
| Angina pectorisCardiac disorders | 1/36 | 0/34 | 0/36 |
| Ankle fractureMusculoskeletal and connective tissue disorders | 1/36 | 0/34 | 0/36 |
| Renal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/36 | 0/34 | 0/36 |
| Event | SRX246 120mg BID | SRX246 160mg BID | Placebo |
|---|---|---|---|
| nauseaGastrointestinal disorders | 7/36 | 9/34 | 4/36 |
| Upper Respiratory Tract InfectionInfections and infestations | 6/36 | 4/34 | 9/36 |
| depressed moodPsychiatric disorders | 8/36 | 8/34 | 4/36 |
| headacheNervous system disorders | 6/36 | 4/34 | 8/36 |
| FatigueGeneral disorders | 3/36 | 5/34 | 2/36 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/36 | 5/34 | 1/36 |
| FallInjury, poisoning and procedural complications | 4/36 | 4/34 | 5/36 |
| Age, Continuous(years) | SRX246 120mg BID | SRX246 160mg BID | Placebo | Total |
|---|---|---|---|---|
| Mean | 51.1 ± 13.2 | 48.9 ± 12.7 | 51.7 ± 10.4 | 50.6 ± 12.1 |
| Sex: Female, Male(Participants) | SRX246 120mg BID | SRX246 160mg BID | Placebo | Total |
|---|---|---|---|---|
| Female | 18 | 17 | 20 | 55 |
| Male | 18 | 17 | 16 | 51 |
| Race/Ethnicity, Customized(Participants) | SRX246 120mg BID | SRX246 160mg BID | Placebo | Total |
|---|---|---|---|---|
| White | 36 | 33 | 36 | 105 |
| Not White | 0 | 1 | 0 | 1 |
| Hispanic/Latino | 2 | 4 | 0 | 6 |
| Not Hispanic/Latino | 34 | 30 | 35 | 99 |
| Missing | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | SRX246 120mg BID | SRX246 160mg BID | Placebo | Total |
|---|---|---|---|---|
| United States | 36 | 34 | 36 | 106 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Sep 2018, 28 months.
Results were first posted in Jul 2023, 4 years 10 months after primary completion.
Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 28 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SRX246
Azevan Pharmaceuticals